IDEAS home Printed from https://ideas.repec.org/p/hhs/ihewps/2022_004.html
   My bibliography  Save this paper

Cancer in Ireland – Disease Burden, Costs and Access to Medicines

Author

Listed:
  • Hofmarcher, Thomas

    (IHE - The Swedish Institute for Health Economics)

  • Ericson, Oskar

    (IHE - The Swedish Institute for Health Economics)

  • Lindgren, Peter

    (IHE - The Swedish Institute for Health Economics)

Abstract

This report provides key statistics about cancer in Ireland. It builds on IHE Comparator Report 2019:7 and provides a comparison of Ireland with other selected countries in Europe. The key findings are the following: The disease burden of cancer: • Cancer has become the leading cause of death in Ireland over the past two decades. • The number of newly diagnosed cancer cases in Ireland has doubled from 12,000 to 24,000 cases since 1995, driven mostly by demographic changes. The economic burden of cancer: • The economic burden of cancer exceeds €320 per capita per year, of which €200 are health expenditure and €120 are costs from productivity losses. • Official aggregated data on health spending on cancer are absent in Ireland, but estimates indicate that per capita spending on cancer in Ireland is similar to the EU-15 average. • The indirect costs of cancer have been decreasing in Ireland since 2000 due to better patient outcomes. Outcomes of cancer patients and spending: • Cancer survival has improved in Ireland, yet survival rates in many cancer types are lower than in other EU-15 countries resulting in hundreds of avoidable deaths every year. • Across Europe, there is a clear pattern of countries spending more on cancer care achieving higher survival rates, which makes spending in Ireland appear less efficient. Access to cancer medicines: • Time to patient access of new EMA-approved cancer medicines is exceptionally long in Ireland compared with the EU-15 countries, reaching almost 2 years. • Once reimbursed, the use of modern cancer medicines in Ireland is close to the EU-15 average, however. • The lack of patient access to modern, effective cancer medicines in Ireland leads to a great loss in life years and quality of life of cancer patients.

Suggested Citation

  • Hofmarcher, Thomas & Ericson, Oskar & Lindgren, Peter, 2022. "Cancer in Ireland – Disease Burden, Costs and Access to Medicines," IHE Report / IHE Rapport 2022:4, IHE - The Swedish Institute for Health Economics.
  • Handle: RePEc:hhs:ihewps:2022_004
    as

    Download full text from publisher

    File URL: https://ihe.se/wp-content/uploads/2022/07/IHE-Report-2022_4_.pdf
    File Function: Full text
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Martin Wenzl & Suzannah Chapman, 2019. "Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward," OECD Health Working Papers 115, OECD Publishing.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jae Ho Jung & Dae Jung Kim & Kangho Suh & Jaeeun You & Je Ho Lee & Kyung In Joung & Dong Churl Suh, 2021. "International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility," IJERPH, MDPI, vol. 18(2), pages 1-14, January.
    2. Marcelien H. E. Callenbach & Rick A. Vreman & Aukje K. Mantel-Teeuwisse & Wim G. Goettsch, 2022. "When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs," IJERPH, MDPI, vol. 20(1), pages 1-12, December.
    3. Russo, Pierluigi & Carletto, Angelica & Németh, Gergely & Habl, Claudia, 2021. "Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey," Health Policy, Elsevier, vol. 125(9), pages 1140-1145.
    4. Olina Efthymiadou, 2023. "Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1023-1031, September.
    5. Natalie Bohm & Sarah Bermingham & Frank Grimsey Jones & Daniela C. Gonçalves-Bradley & Alex Diamantopoulos & Jessica R. Burton & Hamish Laing, 2022. "The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe," PharmacoEconomics, Springer, vol. 40(1), pages 13-29, January.
    6. Karen M. Facey & Jaime Espin & Emma Kent & Angèl Link & Elena Nicod & Aisling O’Leary & Entela Xoxi & Inneke Vijver & Anna Zaremba & Tatyana Benisheva & Andrius Vagoras & Sheela Upadhyaya, 2021. "Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel," PharmacoEconomics, Springer, vol. 39(9), pages 1021-1044, September.
    7. Pierluigi Russo & Matteo Zanuzzi & Angelica Carletto & Annalisa Sammarco & Federica Romano & Andrea Manca, 2023. "Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service," PharmacoEconomics, Springer, vol. 41(1), pages 107-117, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hhs:ihewps:2022_004. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Annette Persson Dietmann (email available below). General contact details of provider: https://ihe.se/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.